Ensign Peak Advisors
GBIO

Ensign Peak Advisors’s Generation Bio GBIO Stock Holding History

Ensign Peak Advisors’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,064
Closed -$132K – 1765
2023
Q1 		$132K Buy
3,064
+1,540
+101% +$74.5K ﹤0.01% 1751
2022
Q4 		$59.9K Buy
1,524
+745
+96% +$39.1K ﹤0.01% 1775
2022
Q3 		$41K Hold
779
– – ﹤0.01% 2247
2022
Q2 		$51K Hold
779
– – ﹤0.01% 2060
2022
Q1 		$57K Hold
779
– – ﹤0.01% 2110
2021
Q4 		$55K Sell
779
-61,997
-99% -$10.8M ﹤0.01% 2135
2021
Q3 		$15.7M Sell
62,776
-10,004
-14% -$2.4M 0.03% 350
2021
Q2 		$19.6M Buy
72,780
+1,122
+2% +$336K 0.04% 320
2021
Q1 		$20.4M Buy
71,658
+42,376
+145% +$13.6M 0.04% 312
2020
Q4 		$8.3M Buy
29,282
+7,385
+34% +$2.37M 0.02% 468
2020
Q3 		$6.77M Buy
21,897
+8,797
+67% +$2.1M 0.02% 538
2020
Q2 		$2.75M Buy
+13,100
New +$2.92M 0.01% 805

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ensign Peak Advisors's GBIO Position: Q2 2023 in Review

Ensign Peak Advisors sold out of Generation Bio (GBIO) in Q2 2023, closing a stake of 3,064 shares — an estimated $132K sold.

Ensign Peak Advisors first reported a position in GBIO in Q2 2020 and held it in 12 quarters. The position peaked at $20.4M in Q1 2021. 79 funds tracked by Wall St. Rank hold GBIO as of Q2 2023.

  • Ensign Peak Advisors reported no remaining Generation Bio position as of Q2 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 3,064 Generation Bio shares in Q2 2023, an estimated $132K.
  • Ensign Peak Advisors first reported a position in Generation Bio in Q2 2020 and held it in 12 quarters.
  • Ensign Peak Advisors's Generation Bio position peaked at $20.4M in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Generation Bio as of Q2 2023.

Based on Ensign Peak Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.